IRIS - Res&Arch Institutional Research Information System - Research & Archive

TIACCI, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.381
EU - Europa 2.909
AS - Asia 2.815
SA - Sud America 478
Continente sconosciuto - Info sul continente non disponibili 371
AF - Africa 70
OC - Oceania 5
Totale 11.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.239
SG - Singapore 1.308
IT - Italia 953
IE - Irlanda 419
BR - Brasile 372
CN - Cina 367
RU - Federazione Russa 334
HK - Hong Kong 308
VN - Vietnam 299
UA - Ucraina 247
DE - Germania 176
FR - Francia 160
FI - Finlandia 150
SE - Svezia 148
KR - Corea 99
GB - Regno Unito 97
BD - Bangladesh 88
IN - India 79
CA - Canada 65
NL - Olanda 55
TR - Turchia 49
IQ - Iraq 36
AR - Argentina 35
MX - Messico 34
PL - Polonia 33
JP - Giappone 25
AT - Austria 24
PK - Pakistan 24
BE - Belgio 23
CO - Colombia 19
EC - Ecuador 19
ES - Italia 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
ZA - Sudafrica 17
SA - Arabia Saudita 16
CH - Svizzera 15
ID - Indonesia 14
MA - Marocco 12
VE - Venezuela 12
CR - Costa Rica 10
PE - Perù 9
PH - Filippine 9
JO - Giordania 8
LB - Libano 8
CL - Cile 7
KZ - Kazakistan 7
MY - Malesia 7
EG - Egitto 6
GR - Grecia 6
BG - Bulgaria 5
ET - Etiopia 5
HN - Honduras 5
JM - Giamaica 5
OM - Oman 5
PA - Panama 5
AU - Australia 4
DZ - Algeria 4
IL - Israele 4
KE - Kenya 4
KG - Kirghizistan 4
NP - Nepal 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
AL - Albania 3
AZ - Azerbaigian 3
BH - Bahrain 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
IR - Iran 3
LT - Lituania 3
PT - Portogallo 3
RO - Romania 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BB - Barbados 2
CG - Congo 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
NE - Niger 2
PS - Palestinian Territory 2
QA - Qatar 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CV - Capo Verde 1
Totale 10.641
Salva come PNG Salva come JPEG
Città #
Singapore 898
San Jose 551
Dublin 419
Chandler 410
Perugia 376
Ashburn 328
Hong Kong 306
San Mateo 223
Santa Clara 168
Council Bluffs 158
Boardman 157
Dong Ket 132
Moscow 132
Jacksonville 111
Lauterbourg 106
Seoul 99
Altamura 95
Medford 92
Princeton 92
Dallas 86
Beijing 81
New York 79
Ann Arbor 77
Lawrence 73
Rome 66
Munich 64
Wilmington 64
Los Angeles 63
Andover 61
The Dalles 55
Ho Chi Minh City 54
Helsinki 48
Des Moines 44
São Paulo 44
Amsterdam 39
Hanoi 36
Turku 36
Piscataway 34
Milan 29
Izmir 26
Houston 25
Saint Petersburg 25
Frankfurt am Main 24
Montreal 24
Nuremberg 24
Brussels 22
Orem 22
Redmond 22
Tokyo 22
Chicago 21
Brooklyn 19
Norwalk 19
London 18
Phoenix 17
Toronto 17
Warsaw 17
Woodbridge 17
Atlanta 16
San Francisco 16
Chennai 15
Mexico City 14
Belo Horizonte 13
Charlotte 13
Manchester 13
Poplar 13
Stockholm 13
Tashkent 13
Denver 12
Johannesburg 12
San Paolo di Civitate 12
Baghdad 11
Bologna 11
Redwood City 10
Rio de Janeiro 10
San José 10
Shanghai 10
Terni 10
Boston 9
Haiphong 9
Jeddah 9
Porto Alegre 9
Recife 9
Brno 8
Columbus 8
Guayaquil 8
Todi 8
Amman 7
Barnet 7
Curitiba 7
Da Nang 7
Dhaka 7
Lahore 7
Mumbai 7
New Orleans 7
Olomouc 7
Bogotá 6
Buffalo 6
Falkenstein 6
Falls Church 6
Florence 6
Totale 6.784
Salva come PNG Salva come JPEG
Nome #
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 189
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 170
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial 158
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma 157
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 149
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 147
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 143
Improved achiral and chiral hplc-uv analysis of ruxolitinib in two different drug formulations 142
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 137
Choroidal vasculature analysis in MEK inhibitor-associated retinopathy 133
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype 132
Aberrant somatic hypermutation in tumor cells of nodular lymphocyte-predominant and classical Hodgkin's lymphoma. 126
Genomics of Hairy cell leukemia 126
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance 124
A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways. 119
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. 119
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 119
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia 118
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 118
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 116
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 115
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 115
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 113
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 113
BRAF mutations in hairy-cell leukemia. 112
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 112
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis 111
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 111
Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 111
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. 109
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 107
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 107
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 105
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 105
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia 105
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors 105
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. 104
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 104
Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors 104
Evolving concepts in the pathogenesis of hairy-cell leukaemia. 103
ALK signaling and target therapy in anaplastic large cell lymphoma 103
BRAF V600E mutation in hairy cell leukemia: From bench to bedside 103
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas [Tiacci and Lazzi are co-senior authors] 103
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor 102
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. 102
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 101
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 100
A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression 100
Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype 100
Overlapping features of therapy-related and de novoNPM1-mutated AML 99
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 98
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 98
Aspects of gene expression in B cell lymphomas 95
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 95
Primary Burkitt's lymphoma of bladder in patient with AIDS. 93
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 92
Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. 91
IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. 91
Hairy Cell Leukemia Biomarkers and Methods of Using Same 91
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 88
One disease, two faces: clonally-related AML and MPDCP with skin involvement 87
Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors 87
PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia 87
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 87
Anaplastic large-cell lymphoma 86
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia 86
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. 85
The genetics of nodal marginal zone lymphoma 85
New treatment options in hairy cell leukemia with focus on BRAF inhibitors 85
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. 85
New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. 84
T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distribution. 81
[Global gene expression analysis and novel signalling pathways in Hodgkin lymphoma] 81
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. 79
The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma 79
HAPLOIDENTICAL TRANSPLANTATION WITH TREG-TCON ADOPTIVE IMMUNOTHERAPY FOR THE CURE OF ACUTE MYELOID LEUKEMIA WITH HIGH-RISK CYTOGENETICS 78
Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. 78
The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. 76
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 76
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 75
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia 74
THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL 73
Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). 72
Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. 72
Lymphoma 72
The authors reply 71
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement 69
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. 69
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia 68
Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy 68
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 67
The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. 66
Hairy cell leukaemia mimicking multiple myeloma 66
An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine 64
IRTA1+ monocytoid B cells in reactive lymphadenitis show a unique topographic distribution and immunophenotype and a peculiar usage and mutational pattern of IgVH genes. 64
Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma. [Tiacci, Mecucci and Kueppers are co-senior authors] 62
Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with moxetumomab pasudotox 62
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall 60
Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas 60
Genomic landscape of virus-associated cancers 60
Totale 9.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.147
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.147
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022757 0 0 0 22 25 8 12 237 59 71 197 126
2022/20231.418 98 268 17 115 101 146 4 49 527 37 43 13
2023/2024607 35 41 43 13 8 9 142 3 51 19 125 118
2024/20251.738 64 174 60 72 236 90 108 123 323 101 250 137
2025/20263.822 278 207 155 364 654 355 656 213 430 305 153 52
2026/20271.068 112 146 283 527 0 0 0 0 0 0 0 0
Totale 11.029